Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia

Venetoclax (VEN) plus azacitidine has become the first-line therapy for elderly patients with acute myeloid leukemia (AML), and has a complete remission (CR) plus CR with incomplete recovery of hemogram rate of ≥70%. However, the 3-year survival rate of these patients is < 40% due to relapse caus...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiang, Qian, Jiejing, Wang, Huafeng, Wang, Yungui, Zhang, Yi, Qian, Pengxu, Lou, Yinjun, Jin, Jie, Zhu, Honghu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088697/
https://www.ncbi.nlm.nih.gov/pubmed/33933163
http://dx.doi.org/10.1186/s40364-021-00288-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088697/
https://www.ncbi.nlm.nih.gov/pubmed/33933163
http://dx.doi.org/10.1186/s40364-021-00288-7

Ejemplares similares